Dr. Paul J. Isikwe is an alumni of Touro College of Pharmacy. He was a part of the fifth graduating class in 2016. After graduating from TCOP, Dr. Isikwe went on to complete a 2-Year Post-Doctoral Biopharmaceutical Fellowship with an emphasis in Managed Care, Market Access, and HEOR with Massachusetts College of Pharmacy and Health Sciences along with Sanofi Genzyme. While at MCPHS, Dr. Isikwe served as an Adjunct Assistant Professor teaching at the College of Pharmacy and in the Physician Assistant Program. He also served as a Preceptor to 3rd and 4th year pharmacy school students.

In Dr. Isikwe’s current role, he serves as a member of the Value, Evidence, and Outcomes team within the US Medical Affairs division at Teva Pharmaceuticals. He oversees communication of medical, scientific, HEOR, pharmacy, and health policy with various payer organizations and integrated delivery networks. Dr. Isikwe is an active member of AMCP, ISPOR, ICPE, ACCP and is currently completing his M.S. degree in Pharmaceutical Value, Access, & Communication.

Clinical Specialty

Immunology, Oncology, Neurology

Education

MS in Pharmaceutical Value, Access, & Communication, (University of Florida), 2021
Biopharmaceutical Fellowship, Massachusetts College of Pharmacy & Health Sciences / Sanofi Genzyme, 2018
PharmD, Touro College of Pharmacy, NY, 2016
BA in Biology, University of Texas, TX, 2012

 

Recent Presentations

“The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic or Episodic Migraine.” Richard B. Lipton, MD, Sanjay K. Gandhi, PhD, Paul Y. Young, MD, MPH, FAHS, Joshua M. Cohen, MD, MPH, FAHS, Ronghua Yang, PhD, Paul J. Isikwe, PharmD

Presented at AMCP 2019 Conference

“Pharmacist Role in Managing Patients with Multiple Sclerosis.” Jennifer Cardone, Paul Isikwe, Lisa Farnett Darren Stam.

Presented at 2018 ACCP Global Conference

“Low Rates of Disease-Modifying Therapy Initiation and Switching After Steroid Treatment of Patients With MS: Treatment Patterns From a US Retrospective Claims-Based Study.” Marie Sanchirico, Amanda Caldwell-Tarr, Paul Isikwe, Lobat Hashemi, Robert Dufour.

Presented at AMCP 2018 Conference

“Low Rates of Disease-Modifying Therapy Initiation and Switching After Steroid Treatment of Patients With MS: Treatment Patterns From a US Retrospective Claims-Based Study.” Marie Sanchirico, Amanda Caldwell-Tarr, Paul Isikwe, Lobat Hashemi, Robert Dufour.

Presented at ECTRIMS 2017 Conference

“Impact of Quality-Based Reimbursement on Physician Practice in Multiple Sclerosis Patient Care.” Thomas Barsanti, Jennifer Cardone, Paul Isikwe, Kevin Duhrkopf

Presented at Nexus 2017 Conference

“Disease-Modifying Therapy Is Associated With Lower Medical Costs in Patients With Multiple Sclerosis With or Without Corticosteroid Treatment: A US Retrospective Claims-Based Study.” Marie Sanchirico, Amanda Caldwell Tarr, Paul Isikwe, Lobat Hashemi, Robert Dufour

Presented at ISPOR-EU 2017 Conference

“Impact of Quality Metrics Requirements on Daily Practice of Advanced Practice Clinicians.” Mary Filipi, Jennifer Ravenscroft, Paul Isikwe, Thomas Barsanti, Marie Sanchirico, Colleen Miller

Presented at CMSC 2017 Conference

 

Memberships and Affiliations

Active member of AMCP, ISPOR, ICPE, and ACCP.

Teaching Responsibilities

SBAN 655 ‐ Introduction to the Pharmaceutical Industry

Hobbies

Cooking, Sports, Music, Reading, Writing